Journal of Hepatocellular Carcinoma

Scope & Guideline

Unveiling the latest breakthroughs in liver oncology.

Introduction

Immerse yourself in the scholarly insights of Journal of Hepatocellular Carcinoma with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN-
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationJ HEPATOCELL CARCINO / J. HEPATOCELL. CARCINOMA
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The Journal of Hepatocellular Carcinoma focuses on advancing the understanding and treatment of hepatocellular carcinoma (HCC) through innovative research methodologies and interdisciplinary approaches.
  1. Clinical Research and Trials:
    The journal publishes studies that investigate various clinical aspects of hepatocellular carcinoma, including treatment efficacy, patient outcomes, and therapeutic strategies across different patient demographics.
  2. Molecular and Genetic Studies:
    Research contributions often explore the molecular mechanisms underlying HCC, including genetic mutations, epigenetic modifications, and their implications for prognosis and treatment.
  3. Imaging and Radiomics:
    The journal emphasizes the role of advanced imaging techniques and radiomic analysis in predicting HCC progression, microvascular invasion, and treatment response.
  4. Immunotherapy and Targeted Therapies:
    A significant focus is placed on the development and clinical application of immunotherapeutic approaches and targeted therapies, particularly in combination with traditional treatments like transarterial chemoembolization.
  5. Biomarkers and Prognostic Models:
    Research on identifying novel biomarkers for early detection, prognosis, and treatment response prediction is a core area, aimed at enhancing personalized medicine in HCC.
  6. Public Health and Disparities:
    The journal also addresses healthcare disparities and the impact of socioeconomic factors on HCC treatment outcomes, contributing to a broader understanding of the disease in diverse populations.
The Journal of Hepatocellular Carcinoma is witnessing a dynamic evolution in its research focus, with several emerging themes gaining traction in recent years.
  1. Artificial Intelligence and Machine Learning:
    Recent publications increasingly utilize AI and machine learning techniques for predictive modeling, enhancing diagnostic accuracy, and personalizing treatment strategies for HCC patients.
  2. Combination Therapy Strategies:
    There is a growing trend towards exploring combination therapies, particularly integrating immunotherapy with traditional treatments, reflecting the need for more effective and comprehensive treatment regimens.
  3. Metabolic and Nutritional Factors:
    Research examining the role of metabolic syndrome, nutrition, and specific metabolic pathways in HCC progression and treatment response is emerging as a significant area of interest.
  4. Patient-Centered Care and Quality of Life:
    Studies focused on patient-reported outcomes, quality of life, and healthcare disparities are becoming more prominent, indicating a shift towards a more holistic approach to HCC management.
  5. Novel Biomarker Discovery:
    There is an increased emphasis on identifying and validating novel biomarkers for early detection and monitoring treatment response, driven by advances in genomic and proteomic technologies.

Declining or Waning

While the Journal of Hepatocellular Carcinoma continues to cover a wide range of topics, certain themes appear to be losing prominence in recent publications.
  1. Traditional Chemotherapy Approaches:
    Research focusing on conventional chemotherapy methods has decreased as newer targeted therapies and immunotherapies gain traction, reflecting a shift in treatment paradigms.
  2. Single-Modality Treatments:
    The emphasis on single-modality treatments, such as isolated surgical resection or standalone chemoembolization, is waning in favor of multimodal approaches that combine various therapies for improved outcomes.
  3. Basic Science without Clinical Application:
    There is a noticeable decline in studies that focus solely on basic science or laboratory findings without direct clinical relevance or application, as the journal increasingly prioritizes translational research.
  4. Epidemiological Studies:
    The frequency of purely epidemiological studies examining HCC incidence and prevalence is decreasing, possibly as the journal shifts towards more intervention-focused research.

Similar Journals

World Journal of Gastrointestinal Oncology

Illuminating the complexities of gastrointestinal cancer research.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

INTERNATIONAL JOURNAL OF ONCOLOGY

Pioneering innovative practices in cancer treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Advancing the Frontiers of Cancer Research.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Molecular Cancer

Pioneering open access to vital cancer insights.
Publisher: BMCISSN: Frequency: 1 issue/year

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

JHEP Reports

Empowering global health through accessible scholarship.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

JHEP Reports, published by ELSEVIER, stands at the forefront of scholarly communication in the fields of Gastroenterology, Hepatology, Immunology and Allergy, and Internal Medicine. As an Open Access journal since 2019, it provides a platform for the dissemination of high-quality research findings, making vital information readily accessible to a global audience. With a commendable impact characterized by a Q1 category ranking across four medical disciplines in 2023, JHEP Reports demonstrates its significance and influence, reflected in its impressive Scopus ranks—#11 in Gastroenterology and #14 in Internal Medicine, amongst others. This esteemed journal not only plays a critical role in advancing knowledge but also fosters collaboration among researchers, practitioners, and students keen on exploring innovations and breakthroughs in health sciences. At RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, JHEP Reports is committed to bridging the gap between research and application, ushering in a new era of informed and effective healthcare solutions.

Journal of Clinical and Translational Hepatology

Advancing hepatology for better patient outcomes.
Publisher: XIA & HE PUBLISHING INCISSN: 2225-0719Frequency: 12 issues/year

Journal of Clinical and Translational Hepatology is an esteemed publication dedicated to advancing the field of hepatology through innovative research and clinical insights. Published by XIA & HE PUBLISHING INC, this journal connects researchers and healthcare professionals in the exploration of liver diseases and their management. With an impact factor that reflects its significant contribution to the discipline, the Journal holds a commendable Q2 classification in Hepatology as of 2023, and it ranks highly in both Gastroenterology and Hepatology categories on Scopus, positioning it within the top 80th percentile of its field. Although the journal is not open access, it provides its audience with invaluable information, encouraging collaboration that aims to translate clinical findings into transformative patient care. With a publication history spanning from 2013 to 2024, the Journal of Clinical and Translational Hepatology has established itself as a vital resource for researchers, clinicians, and students alike, making it a prominent voice in the hepatological community.

HEPATOLOGY RESEARCH

Unveiling the complexities of liver health with cutting-edge research.
Publisher: WILEYISSN: 1386-6346Frequency: 12 issues/year

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.

LIVER INTERNATIONAL

Shaping the future of hepatology with impactful discoveries.
Publisher: WILEYISSN: 1478-3223Frequency: 12 issues/year

LIVER INTERNATIONAL, with its ISSN 1478-3223 and E-ISSN 1478-3231, is a prestigious peer-reviewed journal published by Wiley in the United Kingdom. Established in 2003, it focuses on advancing the field of hepatology, covering a broad spectrum of topics including liver disease, hepatocellular carcinoma, and transplantation. Ranking #10 out of 82 in the Scopus category for Medicine - Hepatology and boasting a remarkable 88th percentile, LIVER INTERNATIONAL has secured its reputation as a leading journal, recognized as Q1 in the 2023 category quartiles. The journal emphasizes accessibility, offering an open access option to ensure that critical research findings reach a wider audience. By facilitating the dissemination of high-quality research, LIVER INTERNATIONAL plays a vital role in shaping contemporary hepatological discourse and bridging academic inquiry with clinical practice, making it an essential resource for researchers, healthcare professionals, and students alike.

Hepatic Oncology

Fostering Collaboration in Hepatic Oncology
Publisher: FUTURE MEDICINE LTDISSN: 2045-0923Frequency: 4 issues/year

Hepatic Oncology is a premier Open Access journal published by Future Medicine Ltd that specializes in the critical intersection of hepatology and oncology. With a focus on advancing knowledge in the diagnosis and treatment of liver cancers, the journal provides a platform for innovative research, reviews, and clinical perspectives that serve as a valuable resource for researchers, clinicians, and students alike. Established in 2016 and evolving over the years, Hepatic Oncology underscores its commitment to accessible scientific communication, having transitioned to open access in 2018 to reach a broader audience. The journal holds a Q4 quartile ranking in the fields of hepatology and oncology for 2023, reflecting its emerging influence and role in contemporary research. Through high-quality articles and a focus on real-world applications, Hepatic Oncology aims to bridge gaps in knowledge while fostering collaboration among professionals dedicated to enhancing patient care in hepatic malignancies.

Liver Cancer

Exploring innovative treatments and strategies for liver cancer.
Publisher: KARGERISSN: 2235-1795Frequency: 6 issues/year

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.